Archive: October, 2009

• Copaxone Used for First-Episode/CIS Halves MS Risk

  PARIS — Early treatment with a key drug to fight multiple sclerosis (MS) nearly halves the risk of progression to the full-blown disease, according to a study [...]

  • Caroline says: Copaxone was studied in first-episode/clinically isolated syndrome "CIS"/possible MS patients and it was found to reduce the risk of clinically definite MS by 45%. That's serious.
     
  
  

  • Merck KGaA Submits Application For Cladribine Tablets In US

    Germany’s Merck KGaA has made further progress in its bid to be the first company to market an oral multiple sclerosis treatment by filing cladribine in the [...]

    • Caroline says: The oral race continues and Merck has pulled ahead just a little bit...this US filing comes a day after Novartis announced positive Phase III data for fingolimod.
       
    
    
    Next Entries »